OPKO Health to Sell Select BioReference Assets to Labcorp for $722M
OPK's $722M BioReference asset sale to Labcorp, with a potential $150M earnout, aims to sharpen its biopharma focus and expand access to the 4Kscore Test.
LH - Labcorp Holdings Inc.
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$346.57
DETAILS
HIGH:
$380.00
LOW:
$306.00
MEDIAN:
$352.00
CONSENSUS:
$346.57
UPSIDE:
9.00%
Stock News
OPKO Health Sheds Diagnostics Businesses in Major Labcorp Deal
Labcorp Holdings Inc. (NYSE:LH) stock traded higher Thursday after the company agreed to acquire select assets of BioReference Health from OPKO Health Inc. (NASDAQ:OPK) in a deal worth up to $872 million.
Three stocks poised to beat estimates this earnings season
Third-quarter earnings season has opened unevenly. JPMorgan, Wells Fargo and Citigroup posted missed results this week, while UnitedHealth topped forecasts for both revenue and profit.
Labcorp Enters into Agreement with OPKO Health to Acquire Select Assets of BioReference Health
Acquisition will expand access to clinical laboratory services, including a broad specialty testing menu for patients and providers nationwide BURLINGTON, N.C. and MIAMI, Fla.
Labcorp and Arianna Huffington's Thrive Global Collaborate to Launch Thrive 5 Health Test
First lab test offered in collaboration with Thrive Global Combines Labcorp's scientific expertise with Thrive Global's behavior change approach to help consumers turn health insights into healthier daily habits Delivers insights from five key cardiometabolic health indicators paired with educational content and recommended Thrive Microsteps® BURLINGTON, N.C., Oct. 13, 2026 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced the launch of the Thrive 5 Health Test, the first lab test offered in collaboration with Arianna Huffington's behavior change technology company, Thrive Global.
Here's Why Labcorp Holdings (LH) is a Strong Value Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Labcorp to Announce Third Quarter 2026 Financial Results on October 28, 2026
BURLINGTON, N.C., Sept. 30, 2026 /PRNewswire/ -- Labcorp Holdings Inc.
Is This the Right Time to Add Labcorp Stock to Your Portfolio?
LH expands specialty testing and consumer services through acquisitions, partnerships and AI, while reimbursement and cost risks remain.
Labcorp (NYSE:LH) Shares Gap Down – Should You Sell?
Labcorp Holdings Inc. (NYSE: LH - Get Free Report) shares gapped down prior to trading on Tuesday. The stock had previously closed at $320.99, but opened at $303.46. Labcorp shares last traded at $313.95, with a volume of 129,255 shares traded. Trending Headlines about Labcorp Here are the key news stories impacting Labcorp this week:
Critical Survey: HCA Healthcare (NYSE:HCA) and Labcorp (NYSE:LH)
HCA Healthcare (NYSE: HCA - Get Free Report) and Labcorp (NYSE: LH - Get Free Report) are both large-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, analyst recommendations, dividends, risk, valuation, profitability and institutional ownership. Dividends HCA Healthcare pays an annual dividend of
Labcorp: The CMS Selloff Represents An Excellent Opportunity - Strong Buy
Labcorp shares dropped sharply after CMS released preliminary 2027 lab-payment rates, aligning Medicare rates closer to private insurers and targeting $1B annual savings. I see the selloff as overdone, with market fears exaggerated by a misunderstanding of the CMS report's impact on LH's bottom line. The proposed cuts only affect Medicare's Clinical Laboratory Fee Schedule, with annual reimbursement reductions capped at 15% and final rates pending.
Labcorp's Future Driven By Clinical Testing Demand, Despite Impact From Medicare Cuts
Labcorp Holdings Inc. is upgraded to Buy, supported by resilient demand for diagnostics and robust Q2 results, despite upcoming Medicare rate cuts. LH outperformed both the S&P 500 and healthcare peers YTD, with strong technical support and positive operating margins. Revenue durability, new test launches, and a diversified biopharma segment bolster LH's growth and risk profile amid regulatory headwinds.
Why Labcorp Holdings Stock Dropped Today
Medicare and Medicaid have been overpaying Labcorp for years, says the government. Starting next year, they plan to cut reimbursement of lab testing by 15%.
Labcorp Holdings Inc. (LH) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Labcorp Holdings Inc. (LH) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Labcorp Holdings Inc. (LH) Analyst/Investor Day Transcript
Labcorp Holdings Inc. (LH) Analyst/Investor Day Transcript
Labcorp Bets Big on AI, Specialty Testing to Drive Growth Through 2029
Labcorp Holdings (NYSE:LH) on Thursday presented a comprehensive growth strategy and long-term financial forecast during its 2026 Investor Day.
Labcorp Highlights Strategic Priorities Driving Durable Growth and Shareholder Value at 2026 Investor Day
Reaffirms full-year 2026 guidance Provides long-term outlook through 2029, with compound annual revenue growth of 5% to 8% and compound annual adjusted earnings per share (EPS) growth of 8.5% to 11.5% Outlines strategic growth priorities driven by a differentiated platform powered by science, technology and global scale Presents long-term value creation framework driven by sustainable growth, strong cash flow generation and disciplined capital deployment BURLINGTON, N.C., Sept. 10, 2026 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today will host its 2026 Investor Day at 9 a.m.
Concurrent Investment Advisors LLC Has $1.50 Million Position in Labcorp Holdings Inc. $LH
Concurrent Investment Advisors LLC grew its holdings in Labcorp Holdings Inc. (NYSE: LH) by 64.4% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 5,369 shares of the medical research company's stock after purchasing an additional 2,103 shares during the
Great Point Partners III Sells MLM Medical Labs to Labcorp
GREENWICH, Conn. and MÖNCHENGLADBACH, Germany--(BUSINESS WIRE)--Great Point Partners (“GPP”), a Greenwich-based private investment firm focused exclusively on the health care industry, is pleased to announce that it has sold GPP III portfolio company, MLM Medical Labs (“MLM”), to Labcorp. MLM is a leading provider of global central and specialty lab services supporting clinical trials, biomarker testing, and drug development in the life sciences and biopharma industries.Rohan Saikia, Managing Di.
Moonwalk Biosciences Announces $70 Million Series B: NYSE Content Update
NYSE issues a pre-market daily advisory direct from the trading floor. NEW YORK, Sept.
Price Targets
Labcorp price target raised to $365 from $350 at Truist
$365.00
(was $320.71)
David MacDonald
·
Truist Financial
Labcorp price target raised to $380 from $361 at UBS
$380.00
(was $307.42)
Kevin Caliendo
·
UBS
Labcorp price target raised to $330 from $320 at Barclays
$330.00
(was $306.96)
Barclays
Labcorp price target raised to $355 from $320 at Mizuho
$355.00
(was $319.17)
Ann Hynes
·
Mizuho Securities
Labcorp price target raised to $338 from $308 at Morgan Stanley
$338.00
(was $308.64)
Morgan Stanley
Labcorp price target raised to $306 from $276 at Deutsche Bank
$306.00
(was $308.69)
Deutsche Bank
Labcorp price target raised to $352 from $338 at Baird
$352.00
(was $315.53)
Robert W. Baird
Labcorp price target raised to $320 from $290 at Barclays
$320.00
(was $315.82)
Barclays
Labcorp price target raised to $334 from $332 at Baird
$334.00
(was $255.97)
Eric Coldwell
·
Robert W. Baird
Labcorp price target raised to $300 from $280 at Evercore ISI
$300.00
(was $274.72)
Evercore ISI
Labcorp price target raised to $300 from $270 at Piper Sandler
$300.00
(was $285.30)
David Westenberg
·
Piper Sandler
Labcorp price target raised to $326 from $313 at Baird
$326.00
(was $276.67)
Robert W. Baird
Labcorp price target raised to $313 from $307 at Baird
$313.00
(was $259.18)
Robert W. Baird
Labcorp price target lowered to $320 from $325 at UBS
$320.00
(was $253.74)
Kevin Caliendo
·
UBS
Labcorp price target lowered to $304 from $313 at Baird
$304.00
(was $259.69)
Robert W. Baird
Leerink on Laboratory Corporation of America (LH): 'Sell-off Unwarranted'
$342.00
(was $261.62)
Michael Cherny
·
Leerink Partners
Labcorp price target raised to $325 from $305 at UBS
$325.00
(was $285.93)
UBS
Labcorp price target raised to $320 from $285 at Mizuho
$320.00
(was $283.71)
Ann Hynes
·
Mizuho Securities
Labcorp price target raised to $320 from $310 at Truist
$320.00
(was $278.42)
Truist Financial
Labcorp price target raised to $305 from $300 at Evercore ISI
$305.00
(was $279.44)
Evercore ISI